BridgeBio Pharma (FRA:2CL) Current Accrued Expense : €79.0 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Current Accrued Expense?

BridgeBio Pharma's Current Accrued Expense for the quarter that ended in Mar. 2024 was €79.0 Mil.

BridgeBio Pharma's quarterly Current Accrued Expense increased from Sep. 2023 (€53.5 Mil) to Dec. 2023 (€60.2 Mil) and increased from Dec. 2023 (€60.2 Mil) to Mar. 2024 (€79.0 Mil).

BridgeBio Pharma's annual Current Accrued Expense declined from Dec. 2021 (€71.9 Mil) to Dec. 2022 (€63.0 Mil) and declined from Dec. 2022 (€63.0 Mil) to Dec. 2023 (€60.2 Mil).

BridgeBio Pharma Current Accrued Expense Historical Data

The historical data trend for BridgeBio Pharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Current Accrued Expense Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

23.52

37.99

71.87

63.04

60.15

BridgeBio Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															59.12	62.37	53.53	60.15	78.99

BridgeBio Pharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

BridgeBio Pharma Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma (FRA:2CL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

BBIO:USA

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

BridgeBio Pharma (FRA:2CL) Headlines

No Headlines